Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees To Acquisition By Private Equity
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B. The post Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees To Acquisition By Private Equity appeared first on Above the Law.
The post Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees To Acquisition By Private Equity appeared first on Above the Law.
